c‐MET Inhibition Is Accompanied by PD‐L1 Upregulation and Immunosuppression‐Related Tumor Microenvironment Changes in Esophageal Squamous Cell Carcinoma, With Enhanced Antitumor Activity in Combination With Anti‐PD‐1 Therapy
ABSTRACT Background c‐MET is implicated in ESCC progression, but whether c‐MET inhibition reshapes immune checkpoint expression and the tumor immune microenvironment remains unclear. Methods ESCC cell lines were treated with Tepotinib, and c‐MET and PD‐L1 expression were examined by Western blotting and immunofluoresce...